SC
AXSM icon

Stephens Consulting’s Axsome Therapeutics AXSM Stock Holding History

Stephens Consulting’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$1.17K – 1284
2025
Q1 		$1.17K Buy
+10
New +$1.14K ﹤0.01% 575
2024
Q3 		– Sell
-20
Closed -$1.61K – 533
2024
Q2 		$1.61K Buy
+20
New +$1.48K ﹤0.01% 538

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Stephens Consulting's AXSM Position: Q2 2025 in Review

Stephens Consulting sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 10 shares — an estimated $1.17K sold.

Stephens Consulting first reported a position in AXSM in Q2 2024 and held it in 2 quarters. The position peaked at $1.61K in Q2 2024. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • Stephens Consulting reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 10 Axsome Therapeutics shares in Q2 2025, an estimated $1.17K.
  • Stephens Consulting first reported a position in Axsome Therapeutics in Q2 2024 and held it in 2 quarters.
  • Stephens Consulting's Axsome Therapeutics position peaked at $1.61K in Q2 2024.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.